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We conducted a retrospective review of conﬁrmed HIV-TB coinfected patients previously enrolled as part of the SAPiT study in
Durban, South Africa. Patients with suspected meningitis were included in this case series. From 642 individuals, 14 episodes of
meningitisin10patientswereidentiﬁed.For8patients,thisepisodeofmeningitiswastheAIDSdeﬁningillness,withcryptococcus
(9/14 episodes) and tuberculosis (3/14 episodes) as the commonest aetiological agents. The combination of headache and neck
stiﬀness(78.6%)wasthemostfrequentclinicalpresentation.Relapsingcryptococcalmeningitisoccurredin3/7patients.Mortality
was 70% (7/10), with 4 deaths directly due to meningitis. In an HIV TB endemic region we identiﬁed cryptococcus followed by
tuberculosisastheleadingcausesofmeningitis.Wehighlighttheoccurrenceoftuberculousmeningitisinpatientsalreadyreceiving
antituberculoustherapy.Thedevelopmentofmeningitisheraldedpooroutcomes,highmortality,andrelapsingmeningitisdespite
ART.
1.Introduction
Tuberculosis (TB) is the most common opportunistic in-
fection in patients with Human Immunodeﬁciency Virus
(HIV). The estimated relative risk of HIV-infected individ-
uals developing TB is 20.6 compared to HIV uninfected, in
populations with a generalized HIV epidemic [1].
HIV contributes signiﬁcantly to the overall incidence,
prevalence and poorer outcomes of meningitis. There is
a predominance of chronic opportunistic meningitides in
HIV-infected individuals with a higher risk of mortality and
impaired cognition [2–6]. It is assumed that positive TB
status would account for a greater proportion of tuberculous
meningitis among HIV-TB coinfected patients as opposed to
cryptococcal meningitis. However, in patients with advanced
HIV infection, cryptococcus is the most common aetiology
[2].
With increasing numbers of HIV-TB coinfected patients
presenting to health facilities and high mortality related to
meningitis, we aim to describe the aetiology, clinical pre-
sentation, and outcomes of meningitis in HIV-TB coinfected
individuals.
2. Methods
WeretrospectivelyreviewedHIV-TBcoinfectedpatientswith
suspected meningitis. Patients 18 years and older, with
conﬁrmed pulmonary TB and HIV, enrolled into the SAPiT
study, presenting with suspected meningitis were included in
this study. The SAPiT study was a prospective randomized
control trial conducted in Durban, South Africa (June 2005–
July 2008), investigating the optimal timing of antiretroviral
therapy (ART) initiation in patients on antituberculous
therapy. All patients in the SAPiT study were sputum smear
positive for mycobacteria on enrollment. They were ran-
domly assigned to three groups, each group initiating ART at
ad i ﬀerent stage in tuberculosis therapy: within 4 weeks after
the start of tuberculosis therapy (early arm), within 4 weeks2 AIDS Research and Treatment
after the completion of the intensive phase of tuberculosis
therapy (post intensive arm), or within 4 weeks of comple-
tion of tuberculosis therapy (postcontinuation arm) [7].
Meningitis was suspected in patients who had meningeal
symptoms(headache,neckstiﬀness,photophobia,vomiting)
alone or occurring with fever, altered level of consciousness,
or focal neurological signs. Data on clinical presentation,
investigations, and outcomes were extracted from records at
the clinical trial site and hospitals to which patients were
admitted. The diagnoses of meningitis were made using
a combination of recorded clinical and cerebrospinal ﬂuid
(CSF) criteria.
(i) Cryptococcal meningitis: diagnosed based on a pos-
itive CSF India ink stain, CSF cryptococcal antigen
testorpatientsinitiatedonsystemicantifungalagents
with positive response.
(ii) Tuberculous meningitis: diagnosed if Mycobacterium
tuberculosis was isolated in the CSF. In the absence
of deﬁnitive microbiologic evidence, tuberculous
meningitis was diagnosed based on neurological
ﬁndings in combination with typical CSF alterations
(lymphocytic predominance, raised protein, reduced
glucose), with exclusion of other aetiologies.
(iii) Acute bacterial meningitis: diagnosed on detection
of bacteria by CSF microscopy or culture, or acute
clinical presentation with characteristic CSF ﬁndings
(neutrophil predominance, raised protein, reduced
glucose), and prompt response to antibacterial drugs
[2, 3].
Patients were excluded if records of their diagnostic infor-
mation were incomplete or unavailable. Recurrent episodes
of meningitis that occurred in patients after discharge from
hospital during the follow-up period were included.
This was a descriptive observational study using fre-
quencies and percentages to summarize categorical data and
means, medians, and ranges to summarize continuous data.
The SAPiT trial was approved by the Biomedical Research
Ethics Committee at the University of KwaZulu-Natal and
the South African government’s Medicines Control Council.
3. Results
From 642 TB-HIV coinfected patients enrolled, 20 (3.1%)
patients presented with clinical features suggestive of menin-
gitis, with 10 (50%) classiﬁed as not having meningitis (two
cerebral tuberculomas, one cerebral toxoplasmosis, three
with normal CSF, and four with insuﬃcient data to support
our case deﬁnitions). Fourteen episodes of meningitis that
metourcasedeﬁnitionsoccurredin10patients,summarized
in Table 1.
Among the patients analyzed, the mean (range) age
was 34 (24–48) years and 4 patients were female. The
mean (range) BMI was 22.13 (15.9–30.2)kg/m2 and median
(range) baseline CD4+ cell count was 13 (2–298)cells/mm3.
For 8 patients, the episode of meningitis under study was the
ﬁrst Acquired Immunodeﬁciency Syndrome (AIDS) illness
experienced. Five patients reported a previous history of
TB and 2 reported a previous history of meningitis, both
receiving antifungal prophylaxis for cryptococcal meningitis
after the ﬁrst episode.
The most common combination of presenting clinical
features was headache and neck stiﬀness, seen in 11 (78.6%)
episodes and the triad of headache, vomiting, and neck
stiﬀness observed in 5 (35.7%) episodes. Only 2 patients
presented with fever.
There were nine (9/14) episodes of cryptococcal menin-
gitis (one with disseminated cryptococcal disease, Patient
3), three (3/14) episodes of tuberculous meningitis (one
concomitantly with suspected neurocysticercosis, patient 9),
and two (2/14) cases of meningitis with mixed aetiology
(Patient 3, acute bacterial and cryptococcal; Patient 7,
cryptococcal and tuberculous).
TB sputum culture testing was done for 8/10 patients
with meningitis: 4 of these sputum samples were taken
within 6 weeks of the diagnosis of meningitis. All 4 sputum
sampleswereculturepositiveforTBandoccurredinpatients
with cryptococcal meningitis. There were no cases of drug-
resistant tuberculosis.
The median number of days (range) to the episode
of meningitis from antituberculous therapy initiation was
109 (32–486) and from ART initiation in the 7 patients
receiving ART was 70 (7–214) days. All patients who were
diagnosed with tuberculous meningitis were already on
antituberculous therapy with 2 patients in the last month of
the continuation phase. Patients 7 and 8 (Table 1)r e c e i v e d
steroids as part of tuberculous meningitis management.
Four patients (Patients 1, 3, 7, 10) had suspected immune
reconstitution inﬂammatory syndrome (IRIS) based on the
temporal association of meningitis to ART initiation.
Of the 10 patients, 7 died, with 4 deaths directly due
to meningitis: cryptococcal infection, 1, tuberculosis, 2,
and 1 patient with mixed cryptococcal and tuberculous
meningitis. From patients receiving ART, four (4/7) died.
The case fatality rate for cryptococcal meningitis alone was
11.1% (1/9) and increased to 22.2% (2/9) when cryptococcal
meningitis contributed to death as part of a mixed infection.
Among the 7 patients with cryptococcal meningitis, 3 had
relapsing episodes. The case fatality rate for tuberculous
meningitisalonewas66.6%(2/3)andincreasedto75%(3/4)
when tuberculous meningitis contributed to death as part of
a mixed infection.
The distribution of deaths among the SAPiT arms was
as follows: 2 deaths in the early arm (1 from meningitis);
2 deaths in the postintensive arm (1 from meningitis); 3
deaths in the postcontinuation arm (2 from meningitis).
Three patients died within 3.5 months after the episode
of meningitis from other causes, attesting to the advanced
immunocompromised state of these patients.
4. Discussion
In this ﬁrst case series evaluating meningitis in conﬁrmed
HIV-TB coinfected patients, we demonstrate that the leading
cause of meningitis is cryptococcus followed by tuberculosis,
which is in keeping with population-based reports from sub-
Saharan Africa investigating meningitis in patients with HIVAIDS Research and Treatment 3
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alone [2]. In this sample of coinfected patients, development
of meningitis was associated with poor outcomes including
relapsing meningitis (30%) and high mortality (40%), even
in patients already initiated on ART (57%). Patients in this
study were severely immunocompromised with low CD4+
cell counts (median 13 cells/mm3), which could account for
the reduced frequency of fever as a presenting complaint and
the high mortality and relapse rates.
The burden of tuberculous meningitis has escalated as
HIV disease progression increases extrapulmonary tuber-
culous risk. As established previously [2], the proportion
of tuberculous meningitis is commonly underestimated
due to its associated diagnostic challenges, speciﬁcally the
inability to isolate mycobacteria in the CSF [2, 4, 8]. In this
study,microbiologicdiagnosisoftuberculousmeningitiswas
further compromised as patients had already received several
weekstomonthsofantituberculoustherapy.Ourstudyhigh-
lighted the important occurrence of tuberculous meningitis
in patients already receiving antituberculous therapy which,
toourknowledge,hasonlybeeninvestigatedoncepreviously,
also in Southern Africa [5]. Antituberculous drug resistance
andTB-associatedIRISshouldbeprincipalconsiderationsin
such patients. Coinfected patients had poorer outcomes with
case fatality rates of 66.7% compared to a case fatality rate of
30%fromreportsoftuberculousmeningitispatientswithout
coinfection [4]. This highlights the need to reevaluate man-
agement of tuberculous meningitis particularly in patients
already exposed to antituberculous therapy. Evaluation of
alternate drugs that optimally penetrate the blood brain
barrier and the timing and overall beneﬁt of steroids in
HIV-associated tuberculous meningitis remains a challenge.
Isoniazid and pyrazinamide are ﬁrst-line antituberculous
drugs with good CSF penetration. Patients who develop
tuberculous meningitis while in the continuation phase of
antituberculous therapy are managed with the retreatment
regimen which includes streptomycin. However, injectable
aminoglycosides have poor distribution in the CSF. The
use of second-line drugs or alternative agents with good
CSF penetration such as cycloserine and ethionamide rather
than the conventional retreatment regimen needs further
investigation [9, 10].
The estimated case fatality rate of cryptococcal meningi-
tis in sub-Saharan Africa of 70% is considerably higher than
in our study [11]. However, our sample is small resulting in
an unstable estimate. Other contributing factors that could
account for this diﬀerential mortality include availability of
dual systemic antifungal agents, the urban location of our
research facility with established systems for rapid triage into
appropriate care and supporting laboratory infrastructure.
Three of seven (42.9%) patients experienced cryptococ-
cal meningitis relapses, exceeding relapse rates reported in
patients with HIV alone (23%). Contributing factors to the
high relapse rate include inadequate clinical and serological
screening for cryptococcal disease with use of appropri-
ate prophylaxis, ﬂuconazole resistance, and cryptococcal
associated IRIS in patients on ART [12]. The underlying
pathophysiologic mechanisms for the higher rates of relapse
in coinfected patients needs further study.
Weacknowledgeseverallimitationsinthisstudy,particu-
larly the small sample size. Patients were admitted to various
facilities and were managed by health care workers with
diﬀering skills and access to laboratory and pharmacological
resources.Asthiswasaretrospectivechartreview,thequality
and completeness of data obtained varied between patients.
Meningitis in HIV-infected individuals can be caused
b yv a r i o u sa e t i o l o g i c a la g e n t s[ 2]. This study demonstrates
cryptococcus as the leading cause of meningitis in HIV-
TB coinfected patients, highlighting the occurrence of
meningitis due to causative agents other than TB, in HIV-
infected patients with sputum culture positive TB. However,
clinicians should be wary that tuberculous meningitis can
occur in patients already receiving antituberculous therapy.
Coinfected patients who developed cryptococcal meningitis
demonstrated a higher relapse rate. The mortality from
meningitis in coinfected patients is high, particularly in
those with tuberculous meningitis, and even in patients
on antiretroviral therapy, emphasizing the necessity for
timely diagnosis of HIV and meningitis and to establish
optimum timing of ART in patients with central nervous
system infections. Our data supports the need for further
research into strategies for early detection of meningitis,
improved diagnostic methods for tuberculous meningitis,
and evaluation of more eﬀective drug regimens to improve
the prognosis of HIV associated meningitis.
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